Composition
| Component | Per vial | Research focus |
|---|---|---|
| TB-500 (thymosin beta-4) | 25 mg | Actin binding, cell migration |
| BPC-157 | 10 mg | Blood vessel formation, tissue models |
| KPV | 10 mg | NF-κB, inflammatory cytokines |
Why this combination?
TB-500 and BPC-157 are studied in animal models of tissue repair through different mechanisms. KPV, a fragment of α-MSH, inhibits inflammatory pathways in studies without affecting pigmentation. No study has examined this exact three-way combination.
Status and quality
None of the components is approved; BPC-157 and TB-500 are on the anti-doping prohibited list. The laboratory detects each component separately. Research use only.







